Company news

Beijing Sun-novo Pharmaceutical Research Co. Ltd. Class A (SSE:688621) news

Beijing Sun-novo Pharmaceutical Research Co. Ltd. Class A news releases on 6ix. Latest, Sep 29, 2026: "Beijing Sun-Novo Pharmaceutical Research Co.…

Beijing Sun-novo Pharmaceutical Research Co. Ltd. Class A (SSE:688621) news

Press releases & updates

"Beijing Sun-Novo Pharmaceutical Research Co., Ltd."Announcement on Voluntary Disclosure of Phase I Clinical Trial Data of STC008 Injection for the Treatment of Cancer Cachexia in Patients with Advanced Solid Tumors

"Beijing Sun-Novo Pharmaceutical Research Co., Ltd."Announcement on Progress of Litigation and Reaching of Settlement

"Beijing Sun-Novo Pharmaceutical Research Co., Ltd."Announcement on Voluntary Disclosure of the Execution of the "ABA001 Project Cooperative Development Agreement"

"Beijing Sun-Novo Pharmaceutical Research Co., Ltd."Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Approval Notice for BTP0427

"Beijing Sun-Novo Pharmaceutical Research Co., Ltd."Announcement on Progress of Cooperative Investment with Private Fund

"Beijing Sun-Novo Pharmaceutical Research Co., Ltd."Announcement on the Use of Certain Raised Funds to Increase the Capital of a Wholly-owned Subsidiary for the Implementation of Fundraising Investment Projects

"Beijing Sun-Novo Pharmaceutical Research Co., Ltd."Announcement on Vesting Results for the 1st Vesting Period of the Initial Grant under the 2025 Restricted Share Incentive Plan

"Beijing Sun-Novo Pharmaceutical Research Co., Ltd."Announcement on Voluntary Disclosure of External Investment

"Beijing Sun-Novo Pharmaceutical Research Co., Ltd."Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

"Beijing Sun-Novo Pharmaceutical Research Co., Ltd."Indicative Announcement on the Transfer by Agreement of Certain Shares of the Company by the Controlling Shareholder and the Actual Controller, and the Resulting Change in Equity Interests

"Beijing Sun-Novo Pharmaceutical Research Co., Ltd."Announcement of Voluntary Disclosure of Semi-annual Performance Forecast for 2026

"Beijing Sun-Novo Pharmaceutical Research Co., Ltd."Special Report on the Use of Previously Raised Funds

"Beijing Sun-Novo Pharmaceutical Research Co., Ltd."Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report

Announcement on Implementation of Dividend Distribution for 2025

Announcement on Participation in the Establishment of Hangzhou Qizhen Zhikang Equity Investment Partnership (Limited Partnership)

Announcement on Progress in Signing of the "Supplementary Agreement to the Technology Development Contract" for STC008 Injection

Announcement on Voluntary Disclosure on the Acceptance of Clinical Trial Application for STC009 Injection

Announcement on Completion of the Board of Directors' Re-election, Election of the Chairman and Members of Special Committees under the Board of Directors, and Appointment of Senior Management Member and Securities Affairs Representative

Announcement on Progress in Cooperation in Investment with a Private Fund

for STC008 Injection

Announcement on Application for Comprehensive Credit Line and Estimated Amount of Guarantees by the Company and Its Subsidiaries

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of ABA001 Injection

Announcement on Postponing Term Change of the Board of Directors and Resignation upon Term Expiration of Partial Independent Directors

Announcement on Voluntary Disclosure of External Investment

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Clinical Trials of BTP4327

Announcement on Cooperative Investment with Private Fund

Announcement on Preliminary Earnings Estimate for 2025

Announcement on Progress in Litigation Involved by the Company

Announcement on Terminating the Issuance of Shares and Convertible Corporate Bonds to Purchase Assets and Raising Supporting Funds and Related Party Transactions, and the Withdrawal of Application Documents

Announcement on Voluntary Disclosure on the Acceptance of Clinical Trial Application for ABA001 Injection

Announcement on Litigation Results of the Company

Announcement on Stock Repurchase, Shareholding Increase and Loan Extension

Announcement on Deferring the Reply to the "Inquiry Letter Regarding the Review of Beijing Sun-Novo Pharmaceutical Research Co.,Ltd.’s Share Issuance and Convertible Bond Issuance for Asset Acquisition and Raising of Supporting Funds, and Related Party Transaction"

Announcement on Signing the Technology Development Agreement for STC008 Injection

Announcement on Voluntary Disclosure of Co-Establishment of a Joint Laboratory

Announcement on Resolutions of the 5th Extraordinary General Meeting in 2025

Announcement on Progress in Cancellation of Sub-subsidiary Nanjing Novostream Pharmaceutical Technology Co., Ltd. and Related Party Transactions

Notice on Convening the 5th Extraordinary General Meeting in 2025

Announcement on Submission of Application Materials for the Purchase of Assets through the Issuance of Shares and Convertible Corporate Bonds and the Collection of Supporting Funds, and the Related Party Transactions to the Shanghai Stock Exchange for Review

Announcement on Resolutions of the 4th Extraordinary General Meeting in 2025

Voluntary Announcement on Completion of Affiliated Company’s Plan to Purchase the Company’s Shares

Announcement on the Self-Inspection Report on the Trading of Shares by Insiders of Inside Information Related to This Transaction

Announcement on Resolutions of the 26th Meeting of the 2nd Board of Directors

Announcement on Convening the Q3 2025 Performance Briefing

Announcement on Resolutions of the 24th Meeting of the 2nd Board of Directors

Announcement on Postponing the 4th Extraordinary General Meeting in 2025 for Another Time

Announcement on Postponing the 4th Extraordinary General Meeting in 2025

Announcement on Convening Investor Briefing on Major Asset Restructuring Matters

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Clinical Trials of BTP4507